Online inquiry

IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13070MR)

This product GTTS-WQ13070MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MADCAM1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_130760.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8174
UniProt ID Q13477
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13070MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2435MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 157
GTTS-WQ15121MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SYD985
GTTS-WQ15562MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ2987MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Angiocept
GTTS-WQ11998MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MM-121
GTTS-WQ5800MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CFZ-533
GTTS-WQ4099MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ4233MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BIIB029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW